Home › Research › Biomarkers
Synergistic Association between Plasma Aβ1-42 and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia
Chiu MJ, Yang SY, Chen TF, Lin CH, Yang FC, Chen WP, Zetterberg H, Blennow K.. ACS chemical neuroscience, 2021-04-07
Topic: Amyloid, tau and blood-test diagnosis
Beta-amyloid (Aβ 1-42 ) triggers the phosphorylation of tau protein in Alzheimer's disease (AD), but the relationship between phosphorylated tau (p-tau) and Aβ 1-42 in the blood is not elucidated. We investigated the association in individuals with AD ( n = 62, including amnesic mild cognitive impairment and dementia), Parkinson's disease ( n = 30), frontotemporal dementia ( n = 25), and cognitively unimpaired controls ( n = 41) using immunomagnetic reduction assays to measure plasma Aβ 1-42 and p-tau181 concentrations. Correlation and regression analyses were performed to examine the relation between plasma levels, demographic factors, and clinical severity. Both plasma Aβ 1-42 and p-tau concentrations were significantly higher in AD and frontotemporal dementia than in the controls and Parkinson's disease. A significant positive association was found between plasma p-tau and Aβ 1-42 in controls ( r = 0.579, P < 0.001) and AD ( r = 0.699, P < 0.001) but not in frontotemporal dementia or Parkinson's disease. Plasma p-tau was significantly associated with clinical severity in the AD in terms of scores of clinical dementia rating ( r = 0.288, P = 0.025) and mini-mental state examination ( r = -0.253, P = 0.049). Regression analysis showed that plasma Aβ 1-42 levels explain approximately 47.7% of the plasma p-tau levels in the AD after controlling age, gender, and clinical severity. While in non-AD participants, the clinical dementia rating explained about 47.5% of the plasma p-tau levels. The disease-specific association between plasma Aβ 1-42 and p-tau levels in AD implies a possible synergic effect in mechanisms involving these two pathological proteins' genesis.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chiu, M. J., Yang, S. Y., Chen, T. F., Lin, C. H., Yang, F. C., Chen, W. P., et al. (2021). Synergistic Association between Plasma Aβ1-42 and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. ACS chemical neuroscience. https://doi.org/10.1021/acschemneuro.1c00010
Vancouver
Chiu MJ, Yang SY, Chen TF, Lin CH, Yang FC, Chen WP, et al. Synergistic Association between Plasma Aβ1-42 and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. ACS chemical neuroscience. 2021. doi:10.1021/acschemneuro.1c00010. PMID: 33825443.
BibTeX
@article{chiu2021-33825443,
author = {Chiu, M. J. and Yang, S. Y. and Chen, T. F. and Lin, C. H. and Yang, F. C. and Chen, W. P. and Zetterberg, H. and Blennow, K.},
title = {{Synergistic Association between Plasma Aβ1-42 and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia}},
journal = {ACS chemical neuroscience},
year = {2021},
doi = {10.1021/acschemneuro.1c00010},
pmid = {33825443},
url = {https://doi.org/10.1021/acschemneuro.1c00010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Both plasma Aβ 1-42 and p-tau concentrations were significantly higher in AD and frontotemporal dementia than in the controls and Parkinson's disease.
- A significant positive association was found between plasma p-tau and Aβ 1-42 in controls ( r = 0.579, P < 0.001) and AD ( r = 0.699, P < 0.001) but not in frontotemporal dementia or Parkinson's disease.
- Plasma p-tau was significantly associated with clinical severity in the AD in terms of scores of clinical dementia rating ( r = 0.288, P = 0.025) and mini-mental state examination ( r = -0.253, P = 0.049).
- Regression analysis showed that plasma Aβ 1-42 levels explain approximately 47.7% of the plasma p-tau levels in the AD after controlling age, gender, and clinical severity.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants62
- Effect size47.7%; 47.5%
- Evidence strengthLow
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 31 of the 58 points we could judge it on, which is 53 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (ACS chemical neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 62 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33825443) |
| Free to read | 2 / 2 | Free to read |
| Points | 31 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 31 of the 58 points we could judge it on is 53 out of 100. |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also tagged “synergistic”
2 studies in the library carry the topic tag “synergistic”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.